skip to content

Market News

PureTech issues Gelesis200 positive safety results

03 May 2016 07:38

PureTech Health has noted that Gelesis has announced positive results from a first-in-human study of Gelesis200, its next-generation product designed for patients with type 2 diabetes.

Gelesis200 is a novel oral capsulated device that seeks to induce weight loss and improve glycaemic control in patients with type 2 diabetes.

Gelesis is a PureTech business focused on the development of first-in-class products to safely induce weight loss and improve glycaemic control.

Story provided by

Related Company: PRTC

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.